IP Verse

Zentiva, K.s. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Zentiva, K.s.

Patent Number:
EP4070788
Title:
Pharmaceutical Formulations
Applicant:
GILEAD SCIENCES, INC.
Opposition Date:
Dec 11, 2023
Patent Number:
EP3294283
Title:
Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure
Applicant:
NOVARTIS AG
Opposition Date:
Dec 8, 2023
Patent Number:
EP4070787
Title:
Pharmaceutical Formulations
Applicant:
GILEAD SCIENCES, INC.
Opposition Date:
Nov 29, 2023
Patent Number:
EP2139494
Title:
Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate
Applicant:
ASTRAZENECA AB
Opposition Date:
Dec 10, 2020
Patent Number:
EP3294285
Title:
Cabazitaxel And Its Use For Treating Cancer
Applicant:
AVENTIS PHARMA S.A.
Opposition Date:
Sep 18, 2020
Patent Number:
EP3335708
Title:
Administration Of Gamma Hydroxybutyrate With Monocarboxylate Transporters
Applicant:
JAZZ PHARMACEUTICALS IRELAND LIMITED
Opposition Date:
Sep 2, 2020
Patent Number:
EP3038654
Title:
New Use
Applicant:
NOVARTIS AG
Opposition Date:
Jul 23, 2020
Patent Number:
EP2371361
Title:
Methods To Mobilize Progenitor/Stem Cells
Applicant:
GENZYME CORPORATION
Opposition Date:
May 7, 2020
Patent Number:
EP3395339
Title:
Rapid Dissolution Formulation Of A Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Jan 17, 2020
Patent Number:
EP3103448
Title:
Pharmaceutical Compositions Comprising An S1P Modulator
Applicant:
NOVARTIS AG
Opposition Date:
Dec 9, 2019

Competitors of Zentiva, K.s.

NOVARTIS AG

BRISTOL-MYERS SQUIBB COMPANY

EURO-CELTIQUE S.A.

Want to track Zentiva, K.s.?

Feel free to send us a message here and we will get back to you